Security Snapshot

Insight Molecular Diagnostics Inc. - Common Stock, no par value (IMDX) Institutional Ownership

CUSIP: 68235C206

13F Institutional Holders and Ownership History from Q2 2023 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

34

Shares (Excl. Options)

16,651,600

Price

$7.50

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock, no par value
Symbol
IMDX on Nasdaq
Shares outstanding
32,305,051
Price per share
$3.24
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
16,651,600
Total reported value
$124,888,014
% of total 13F portfolios
0%
Share change
+368,716
Value change
+$2,765,695
Number of holders
34
Price from insider filings
$3.24
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • IMDX - Insight Molecular Diagnostics Inc. - Common Stock, no par value is tracked under CUSIP 68235C206.
  • 34 institutions reported positions in Q4 2025.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 34 to 3 between Q4 2025 and Q1 2026.
  • Reported value moved from $124,888,014 to $811,084.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 34 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 68235C206?
CUSIP 68235C206 identifies IMDX - Insight Molecular Diagnostics Inc. - Common Stock, no par value in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Insight Molecular Diagnostics Inc. - Common Stock, no par value (IMDX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BROADWOOD PARTNERS, L.P. 37% -7% $90,615,668 +$3,913,042 12,082,089 +4.5% Neal C. Bradsher 10 Feb 2026
AWM Investment Company, Inc. 10% +31% $9,685,464 +$5,257,076 2,857,069 +119% AWM Investment Company, Inc. 31 Mar 2025

As of 31 Dec 2025, 34 institutional investors reported holding 16,651,600 shares of Insight Molecular Diagnostics Inc. - Common Stock, no par value (IMDX). This represents 52% of the company’s total 32,305,051 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Insight Molecular Diagnostics Inc. - Common Stock, no par value (IMDX) together control 52% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BROADWOOD CAPITAL INC 35% 11,410,100 0% 5.2% $85,575,750
AWM Investment Company, Inc. 8.7% 2,814,230 -0.29% 2% $21,106,725
PURA VIDA INVESTMENTS, LLC 2.9% 947,134 0% 27% $7,103,505
VANGUARD GROUP INC 1.6% 526,675 +8.2% 0% $3,950,064
GEODE CAPITAL MANAGEMENT, LLC 0.71% 230,971 +16% 0% $1,733,670
BlackRock, Inc. 0.41% 131,361 +49% 0% $985,208
683 Capital Management, LLC 0.24% 77,204 0.05% $579,030
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.22% 72,451 0% $543,383
MILLENNIUM MANAGEMENT LLC 0.19% 61,377 -16% 0% $460,328
NORTHERN TRUST CORP 0.15% 48,858 +49% 0% $366,435
STATE STREET CORP 0.15% 47,754 +14% 0% $358,155
JANE STREET GROUP, LLC 0.13% 42,469 0% $318,517
FNY Investment Advisers, LLC 0.13% 40,584 -24% 0.09% $304,000
MORGAN STANLEY 0.11% 35,913 -42% 0% $269,348
Qube Research & Technologies Ltd 0.09% 28,351 0% $212,633
OMERS ADMINISTRATION Corp 0.08% 26,164 0% $196,230
OSAIC HOLDINGS, INC. 0.07% 24,136 +115% 0% $181,019
GOLDMAN SACHS GROUP INC 0.07% 23,965 0% $179,738
CITADEL ADVISORS LLC 0.05% 15,647 +33% 0% $117,353
RENAISSANCE TECHNOLOGIES LLC 0.04% 13,400 -43% 0% $100,500
Hudson Bay Capital Management LP 0.04% 13,061 0% $97,958
Private Advisor Group, LLC 0.03% 10,416 0% 0% $78,120
EverSource Wealth Advisors, LLC 0.02% 5,000 0% 0% $37,500
UBS Group AG 0.01% 2,941 +8.4% 0% $22,058
ORG Partners LLC 0% 450 0% 0% $3,375

Institutional Holders of Insight Molecular Diagnostics Inc. - Common Stock, no par value (IMDX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 247,447 $811,084 +$677,976 $3.24 3
2025 Q4 16,651,600 $124,888,014 +$2,765,695 $7.50 34
2025 Q3 16,282,884 $54,051,121 +$296,694 $3.32 27
2025 Q2 15,248,594 $46,050,393 +$442,513 $3.02 29
2025 Q1 16,047,858 $49,105,818 +$23,516,169 $3.06 29
2024 Q4 8,368,639 $19,916,902 +$2,876,004 $2.38 25
2024 Q3 7,107,091 $20,255,014 +$3,161,741 $2.85 19
2024 Q2 5,990,280 $17,670,609 +$7,170,223 $2.95 21
2024 Q1 3,559,240 $10,429,392 -$189,496 $2.93 22
2023 Q4 3,624,342 $9,059,295 -$247,783 $2.50 24
2023 Q3 3,718,862 $11,617,455 +$11,614,005 $3.12 26
2023 Q2 15,000 $3,450 +$3,450 $0.23 1